Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 30 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
EquiVita Genetics from Hasselt, company number BE0772385165, closed financial year 2025 with a result of € -62,266 after tax. For that financial year EquiVita Genetics recorded a gross margin of € 21,465 and equity of € -102,010. Compared with financial year 2024, the result moved from € -137,373 to € -62,266. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 26, 2026.
€ -102,010
▼ € 62,266 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -62,266
▲ 55 % less loss than in 2024
Profit after tax over the fiscal year.
€ 492
▼ 95% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -358,210.
People and assets in 2025
€ 39,353
▼ 30% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 100,800
▲ 68% vs 2024
Loans from banks and other lenders, long and short.
€ 1,726
▼ 85% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -1,837 | € -92,441 | € -60,515 | € 21,465 | ▲ € 81,980 |
| Profit after taxes | € -2,687 | € -155,884 | € -137,373 | € -62,266 | ▲ € 75,107 |
| Equity | € 253,513 | € 97,629 | € -39,744 | € -102,010 | ▼ € 62,266 |
| Total debts | € 9,388 | € 5,878 | € 78,013 | € 102,526 | ▲ 31% |
| Cash | € 255,024 | € 50,292 | € 10,826 | € 492 | ▼ 95% |
| Retained profit | € -2,687 | € -158,571 | € -295,944 | € -358,210 | ▼ € 62,266 |
| Bank debt | € 0 | € 0 | € 60,000 | € 100,800 | ▲ 68% |
| Balance sheet total | € 262,901 | € 103,506 | € 38,269 | € 516 | ▼ 99% |
Key figures of EquiVita Genetics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to EquiVita Genetics?
What happened at EquiVita Genetics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 62,266. Source: NBB ↗
- Koen Goyens became a director. NBB
- New establishment in Hasselt. KBO
- Start of the company according to the CBE. KBO
- Charlotte Vertessen became a director. NBB
- Viktor-Jan Vertessen became a director. NBB
In short
From € 2,687 loss in 2022 to € 62,266 loss in 2025.
Paid € 630 in corporate taxes since 2022.
A new publication or filing at EquiVita Genetics? We notify you, reason included.
Follow EquiVita GeneticsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of CUR@DOMUM comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
EquiVita GeneticsBehind EquiVita Genetics are Charlotte Vertessen, Viktor-Jan Vertessen and Koen Goyens. The shares are held by CUR@DOMUM (33.3%).
Directors
According to the 2025 annual accounts
since 2021
since 2021
Koen Goyens
Director
since 2022
Shareholders
33.3%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Tongersesteenweg 13A box 2
3720 Hasselt
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0772.385.165
- VAT number
- BE 0772.385.165
- Registered office
- Tongersesteenweg 13A bus 2, 3720 Hasselt
- Names & denominations
- EquiVita Genetics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 9 August 2021
- Peppol
- Active · Active since 30 Oct 2023
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Ondersteunende activiteiten in verband met de veeteelt
Fokken en houden van paarden en andere paardachtigen
Overige technische testen en toetsen
Overige zakelijke dienstverlening, neg
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied